Nuevocor is a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies.

The company’s lead programme is an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene. The company also plans to address other untreatable cardiomyopathies using their novel target discovery platform.

LMNA mutations are the number 2 cause of familial DCM, affecting approximately 60,000 people in the US and EU alone. The mutation confers amongst the worst prognosis of all DCM, with increased risk of arrhythmogenic DCM and sudden cardiac death. Being an autosomal dominant disease characterized by gain-of-function of the mutant Lmna protein, conventional gene replacement therapies would be ineffective for LMNA DCM. Nuevocor’s innovative approach to gene therapy, exploiting the potential of genetic suppressors to change the course of these diseases, aims to circumvent this roadblock.

Founded in 2020 and based in Singapore, Nuevocor’s approach is based on decades of research into fundamental mechanisms underlying LMNA-associated disease enabled by development of novel technologies on the part of scientific co-founders Colin Stewart and Brian Burke of the Agency for Science, Technology and Research (A*STAR).